



FOR IMMEDIATE RELEASE

Cancer Advances Announces \$48.5 Million Funding Commitment

Durham, NC, October 26, 2015—[Cancer Advances Inc.](#), a wholly owned subsidiary of Cato Holding Company, has entered into an agreement with Keyholder Investments Ltd. to raise up to \$48.5 million to further the development of the company's immune-modulating Polyclonal Antibody Stimulator ("PAS"), to treat gastrin-dependent diseases.

Cancer Advances, Inc. holds a broad technology and intellectual property portfolio focused on neutralizing a key signaling hormone that is responsible for proliferation and tumorigenesis in multiple cancers. Cancer Advances' products are specifically directed at inhibiting the binding of gastrin to cellular membrane receptors to down-regulate the growth and proliferation pathways responsible for a cancer's rapid metastasis and expansion. Such an inhibitory effect is achieved via the administration of PAS, which stimulates the patient to produce polyclonal antibodies directed against gastrin. PAS has been evaluated in over twenty controlled clinical studies focused on three gastrointestinal cancers – pancreatic, gastric and colorectal.

"We are excited about entering the next phase of development of our product, and these investment funds will be critical in allowing us to achieve completion of our research and development," says Lynda Sutton, President of Cancer Advances Inc.

About Cancer Advances Inc.

Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

⇒ OVER

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.

Cancer Advances
P | 919-361-2162
E | info@canceradvancesinc.com
www.canceradvancesinc.com

About Keyholder Investments Ltd.

Keyholder Investments Ltd. provides a financing solution for innovative and potentially profitable products in the field of Pharma using a unique methodology that is an attractive alternative to venture capital or equity dilution. For investors, Keyholder provides access to asset-backed investment opportunities that are both leveraged for profit and reduced in risk as a result of well-negotiated terms and enduring asset value.

Please visit our product page for more information on what is in development: <http://www.canceradvancesinc.com/product.html>

Contact: Lynda Sutton
President Cancer Advances, Inc.
Phone: 919-361-2162
Email: info@canceradvancesinc.com
www.canceradvancesinc.com

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.